$0.0600
-0.0030 (-4.76%)
At Close: Jun 03, 2026
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 12)
10X Genomics Inc (NASDAQ:...
Oct 07, 2020 (The Expresswire) --
Global “Nash Drugs Market” research report offers qualitative and quantitative insights in relation to industry growth...
The Daily Biotech Pulse: Mesoblast Slumps On FDA Rejection, AstraZeneca's Breakthrough Therapy Designation, 3 IPOs
12:00am, Friday, 02'nd Oct 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 1)
10X Genomics Inc (NASDAQ:...
GENFIT SA (GNFT) CEO Pascal Prigent on Q2 2020 Results - Earnings Call Transcript
01:49am, Thursday, 01'st Oct 2020
GENFIT SA (NASDAQ:GNFT) Q2 2020 Results Conference Call September 30, 2020 04:30 PM ET Company Participants Stefanie Magner - Deputy Director, Legal Affairs Pascal Prigent - CEO Dean Hum - Chief Scien
Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral First-in-Class Direct AMPK Activator
12:00am, Thursday, 01'st Oct 2020
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, in
Can-Fite Selected to Deliver Late-Breaking Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases
COVID-19 Forces One of the Biggest Surges in Technology Investment in History, Finds World’s Largest Technology Leadership Survey
12:00am, Tuesday, 22'nd Sep 2020
COVID-19 forces one of the biggest surges in tech investment in history, finds Harvey Nash/KPMG CIO Survey.
U.S. IPO Weekly Recap: Snowflake's IPO Breaks Records In A Diverse 15-IPO Week
01:54pm, Saturday, 19'th Sep 2020
In the busiest week yet for the 2020 IPO market, 15 IPOs raised $8.7 billion. Snowflake took the spotlight, completing the largest software IPO ever and bagging the biggest billion-dollar pop in two d
EDISON, NJ / ACCESSWIRE / September 17, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a biopharmaceutical company focused on the development of therapeutic drugs for the treat
Résultats financiers du 1er semestre 2020 et point sur l'activité
08:00pm, Wednesday, 16'th Sep 2020
Trésorerie et équivalents de trésorerie à 52,3 M€ au 30 juin 2020
Succès de l'introduction en bourse sur le Nasdaq Global Market, avec une levée de 107,7 M$ (94,9 M€) prolongeant la vis
Résultats financiers du 1er semestre 2020 et point sur l’activité
12:00am, Wednesday, 16'th Sep 2020
Trésorerie et équivalents de trésorerie à 52,3 M€ au 30 juin 2020Succès de l'introduction en bourse sur le Nasdaq Global Market, avec une levée de 107,7...
Poxel publie ses résultats financiers du premier semestre 2020 et dresse un bilan de ses activités
12:00am, Tuesday, 15'th Sep 2020
Regulatory News: POXEL SA (Paris:POXEL) (Euronext : POXEL — FR0012432516), société biopharmaceutique spécialisée dans le développement de traitements
Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-297, its Highly Potent and Targeted Follow-On Farnesoid X Receptor Agonist for NASH
Enanta Pharmaceuticals Presents New Data from its Hepatitis B and Non-Alcoholic Steatohepatitis Programs at the Digital International Liver Congress
Sign In
Buy HEPA